Successful Use of Kidneys from a Deceased Donor with Active Herpes Zoster Infection.


Journal

Case reports in transplantation
ISSN: 2090-6943
Titre abrégé: Case Rep Transplant
Pays: United States
ID NLM: 101591863

Informations de publication

Date de publication:
2021
Historique:
received: 11 06 2021
accepted: 04 08 2021
entrez: 26 8 2021
pubmed: 27 8 2021
medline: 27 8 2021
Statut: epublish

Résumé

The limited donor pool and increasing recipient wait list require a reevaluation of kidney organ suitability for transplantation. Use of higher infectious risk organs that were previously discarded may help improve access to transplantation and reduce patient mortality without placing patients at a higher risk of poor posttransplant outcomes. There is very little data available regarding the safe use of kidney organs from deceased donors with varicella zoster virus infection at the time of organ retrieval. The use of kidney organs from donors with active herpes zoster infection appears to be a safe option to expand the kidney donor pool.

Sections du résumé

BACKGROUND BACKGROUND
The limited donor pool and increasing recipient wait list require a reevaluation of kidney organ suitability for transplantation. Use of higher infectious risk organs that were previously discarded may help improve access to transplantation and reduce patient mortality without placing patients at a higher risk of poor posttransplant outcomes. There is very little data available regarding the safe use of kidney organs from deceased donors with varicella zoster virus infection at the time of organ retrieval.
CONCLUSIONS CONCLUSIONS
The use of kidney organs from donors with active herpes zoster infection appears to be a safe option to expand the kidney donor pool.

Identifiants

pubmed: 34434591
doi: 10.1155/2021/7719041
pmc: PMC8382547
doi:

Types de publication

Case Reports

Langues

eng

Pagination

7719041

Informations de copyright

Copyright © 2021 Amanda J. Vinson et al.

Déclaration de conflit d'intérêts

AV and KW have accepted consultancy fees from Paladin Labs Inc. but declare no conflict of interest. There were no other potential conflicts identified.

Références

MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40
pubmed: 17585291
Transplant Proc. 2012 Nov;44(9):2814-7
pubmed: 23146530
Transplantation. 2017 Dec;101(12):e351-e352
pubmed: 28749818
Am J Transplant. 2013 May;13(5):1227-34
pubmed: 23621162
Ann Intern Med. 2018 Apr 17;168(8):533-540
pubmed: 29507971
N Engl J Med. 2017 Jun 15;376(24):2394-2395
pubmed: 28459186
Transplantation. 2000 Jul 15;70(1):211-3
pubmed: 10919605
Transplantation. 2014 Aug 27;98(4):365-9
pubmed: 25243510
Am J Transplant. 2009 Dec;9 Suppl 4:S108-15
pubmed: 20070670
Transpl Infect Dis. 2011 Feb;13(1):15-23
pubmed: 20636480
J Heart Lung Transplant. 2008 Jan;27(1):11-6
pubmed: 18187081

Auteurs

Amanda J Vinson (AJ)

Division of Nephrology, Department of Medicine, Nova Scotia Health, Halifax, NS, Canada.

Prakash Chauhan (P)

Division of General Surgery, Department of Surgery, Nova Scotia Health, Halifax, NS, Canada.

Christopher Daley (C)

Multi-Organ Transplant Program, Nova Scotia Health, Halifax, NS, Canada.

Himanthi De Silva (H)

Division of Nephrology, Department of Medicine, Nova Scotia Health, Halifax, NS, Canada.

Karthik K Tennankore (KK)

Division of Nephrology, Department of Medicine, Nova Scotia Health, Halifax, NS, Canada.

Paul Bonnar (P)

Division of Infectious Disease, Department of Medicine, Nova Scotia Health, Halifax, NS, Canada.

Kenneth A West (KA)

Division of Nephrology, Department of Medicine, Nova Scotia Health, Halifax, NS, Canada.

Classifications MeSH